NASDAQ:KPRX Kiora Pharmaceuticals Q3 2025 Earnings Report $2.60 -0.03 (-1.14%) Closing price 06/11/2026 04:00 PM EasternExtended Trading$2.56 -0.04 (-1.54%) As of 06/11/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Kiora Pharmaceuticals EPS ResultsActual EPS$0.01Consensus EPS -$0.72Beat/MissBeat by +$0.73One Year Ago EPSN/AKiora Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$0.75 millionBeat/MissN/AYoY Revenue GrowthN/AKiora Pharmaceuticals Announcement DetailsQuarterQ3 2025Date11/7/2025TimeBefore Market OpensConference Call DateFriday, November 7, 2025Conference Call Time6:00AM ETUpcoming EarningsKiora Pharmaceuticals' Q2 2026 earnings is estimated for Friday, August 7, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Kiora Pharmaceuticals Earnings HeadlinesKiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive PlanJune 11 at 6:51 AM | tipranks.comKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 8, 2026 | finanznachrichten.deIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analyst Lance Ippolito says the real opportunity is elsewhere. He's identified 5 dirt-cheap stocks at the forefront of this mega-IPO, including a space ticker that Goldman Sachs, BlackRock, and Morgan Stanley are all buying, a rare resource miner Elon's entire empire depends on, and the chip supplier Starlink satellites can't function without. Access his free SpaceX Investing Blackbook before IPO day arrives. | InvestPub (Ad)Why did KPRX stock surge 17% pre-market today?April 7, 2026 | msn.comKiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive AdvisorsApril 7, 2026 | finance.yahoo.comKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive AdvisorsApril 7, 2026 | finanznachrichten.deSee More Kiora Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kiora Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiora Pharmaceuticals and other key companies, straight to your email. Email Address About Kiora PharmaceuticalsKiora Pharmaceuticals (NASDAQ:KPRX) (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision. The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders. KIO-100 has completed initial Phase 1 safety studies, demonstrating tolerability and preliminary signs of localized immune modulation without systemic exposure. Kiora’s second program, KIO-301, leverages optogenetic therapy to introduce light-sensitive proteins into retinal cells, offering a potential treatment for retinitis pigmentosa and other degenerative retinal diseases. This platform aims to restore visual function by converting surviving retinal neurons into artificial photoreceptors, and it is currently advancing through preclinical development and manufacturing scale-up. Headquartered in the United States, Kiora collaborates with academic institutions and contract research organizations to support its clinical and preclinical programs. The company’s leadership team comprises experienced executives and scientists drawn from both ophthalmology and biotechnology sectors, all working toward delivering novel treatments for patients with unmet visual needs.View Kiora Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Spotify's "North Star" Outlook Was Music to Investors EarsCracker Barrel Surges 23% as Earnings Beat Signals Turnaround ProgressChewy’s Growth Engine Is Stronger Than the Market ThinksCasey’s Is Looking Like a Hot Buy as Growth, Buybacks, and Guidance AlignThe “Duck Stock” Keeps Quietly Making Money for ShareholdersEverpure: AI Storage Uncertainty Overshadows Breakneck GrowthAs Shares Fall, Analyst Are Boosting their Broadcom Price Targets Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
